Search Results 611-620 of 18043 for Alopecia

1. A Study to Evaluate Triapine Combined with Lutetium Lu 177 Dotatate for Gastroenteropancreatic Neuroendocrine Tumors - Mayo Clinic

   Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > Grade 1) with the exception of alopecia.

2. Behcet disease - Symptoms and causes - Mayo Clinic

   Behcet (beh-CHET) disease, also called Behcet syndrome, is a rare condition. It causes blood vessel swelling, called inflammation, throughout the body. Behcet ...

3. Genetic Analysis in Blood and Tumor Samples From Patients With Advanced or Metastatic Estrogen Receptor Positive and HER2 Negative Breast Cancer Receiving Palbociclib and Endocrine Therapy - Mayo Clinic

   Toxicities related to all prior anticancer therapies must have resolved or stabilized, apart from alopecia and peripheral neuropathy. Note: Peripheral ...

4. A Study of Nivolumab and Multi-fraction Stereotactic Radiosurgery with or without Ipilimumab in Treating Participants with Recurrent Grade II-III Meningioma - Mayo Clinic

   Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > grade 1); however, alopecia, sensory ...

5. LC-MS/MS lowers diagnostic thresholds for androgen-producing tumors or pathological hyperandrogenism in women - Mayo Clinic

   52 (58%) women were diagnosed with polycystic ovary syndrome (PCOS). Women with APT were more likely to have male-pattern alopecia documented on physical ...

6. A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency - Mayo Clinic

   Adverse effect of prior therapy not resolved to CTCAE Grade 1 or below with the exception of alopecia. Ongoing Grade 2 non-hematologic toxicity related to ...

7. A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer - Mayo Clinic

   * Toxicities from previous anti-cancer therapies that have not resolved to baseline levels or to Grade 1 or less except for alopecia and peripheral neuropathy.

8. Radiation Therapy with Durvalumab or Cetuximab to Treat Patients with Locoregionally Advanced Head and Neck Cancer who Cannot Take Cisplatin - Mayo Clinic

   Patients with vitiligo or alopecia;; Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement;; Any chronic skin ...

9. Safety Study of PLX3397 and Paclitaxel in Patients With Advanced Solid Tumors - Mayo Clinic

   ... alopecia prior to C1D1; Age eighteen years or older; ECOG performance status 0-2, inclusive; Anticipated life expectancy of at least 12 weeks; Adequate bone ...

10. Amg 510 (Sotorasib) With Or Without Panitumumab In Advanced Solid Tumors: A Combomatch Treatment Trial - Mayo Clinic

    Patients must have recovered to CTCAE Grade 1 or better from any adverse events due to prior cancer therapy (with the exception of alopecia). Patient must ...